The Top Ten Biotech Stocks Right Now

Why it ranks first: Ultragenyx is the only company on the current page with two separate FDA decisions inside the active review window. DTX401 targets glycogen storage disease type Ia, while UX111 targets Sanfilippo syndrome type A. The programs address different diseases, use different clinical packages and represent two distinct regulatory opportunities. That does not eliminate risk, but it prevents the entire current thesis from resting on one coin flip.

The FDA accepted the DTX401 BLA with Priority Review and assigned an August 23 action date. Ultragenyx has also said that the agency did not anticipate an Advisory Committee at the time of acceptance. For UX111, the FDA accepted the resubmission and assigned a September 19 action date. The package includes long-term follow-up extending as far as eight years for some participants, an important consideration for a progressive pediatric neurodegenerative disease.

What matters most before the dates: any FDA communication concerning inspections, manufacturing readiness, labeling, Risk Evaluation and Mitigation Strategy requirements, or post-approval commitments. In rare-disease gene therapy, an apparently positive efficacy package can still be delayed by production or comparability questions. Beyond the two PDUFAs, the Phase 3 Aspire study of GTX-102 enrolled 129 patients and is now guided for a September or October 2026 data readout, adding a third major second-half value inflection.

Merlintrader view: $RARE offers the best balance of catalyst density, corporate quality and survivability. It may not deliver the most extreme percentage move in the group, but it has the most complete current setup.

The central catalyst: Pharvaris expects topline results from CHAPTER-3 during the third quarter of 2026. The pivotal study evaluates once-daily extended-release deucrictibant for prophylactic treatment of hereditary angioedema. Approximately 81 participants were randomized 2:1 to active treatment or placebo for 24 weeks.

This is one of the cleaner clinical setups on the list because the molecule is not entering the pivotal stage without supporting evidence. Deucrictibant has generated data in both acute and prophylactic settings, and the same oral bradykinin B2 receptor antagonism underpins the broader program. The immediate-release formulation also reached a major regulatory milestone when its U.S. NDA was accepted in July 2026, although its PDUFA date falls in April 2027 and therefore sits outside the current ranking’s active review window.

The data details that matter: annualized attack rate, proportion of attack-free patients, consistency across subgroups, rescue-medication use, treatment discontinuations and any signal that efficacy weakens over time. A headline beat is important, but competitive positioning will depend on the entire profile.

Merlintrader view: $PHVS is the best pure pivotal-readout setup in the ranking. It still carries normal Phase 3 risk, but the combination of prior validation, a defined market and adequate capital gives the event a more balanced structure than many binary biotech readouts.

Why it enters the Top Ten: Definium now has one of the densest late-stage catalyst stacks in the sector. On August 6 the company confirmed that topline results from the Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder are expected in the week of August 10, followed by Phase 3 PANORAMA results in September 2026. Those readouts arrive immediately after a separate Phase 3 study, EMERGE in major depressive disorder, reported a positive result.

EMERGE randomized 149 participants and met its primary endpoint and all key secondary efficacy endpoints. Definium reported a placebo-adjusted 8.1-point improvement in MADRS at Week 6 with Cohen’s d of 0.83 and p<0.0001, followed by a 7.3-point placebo-adjusted difference at Week 12. DT120 ODT was reported as generally well tolerated, with no serious adverse events and no suicidality signal observed in that trial. The GAD program is distinct, however, so the MDD result is supportive evidence rather than proof that VOYAGE or PANORAMA will succeed.

What matters in VOYAGE: the Week-12 change in Hamilton Anxiety Rating Scale versus placebo, effect size, durability, response/remission analyses, treatment-emergent adverse events and the consistency of the result with the broader DT120 dataset. PANORAMA then becomes the replication test, with its additional 50 µg control arm providing another layer of interpretability.

Merlintrader view: $DFTX is the most important new entrant in the August 7 ranking. A Phase 3 readout guided for the week of August 10, a second Phase 3 readout in September, supportive Phase 3 MDD data and an exceptionally strong balance sheet give it a better quality-adjusted profile than the prior No. 3 setup. It remains a high-risk clinical story, but it is now too important to omit.

Tenax expects to report topline data in August from LEVEL, a registrational Phase 3 trial evaluating oral levosimendan, TNX-103, in pulmonary hypertension associated with heart failure with preserved ejection fraction. More than 230 patients were randomized, and the results are scheduled for a late-breaking clinical-science presentation at the European Society of Cardiology Congress on August 29.

This is a strong catalyst because PH-HFpEF is a large and difficult disease setting with no therapy specifically approved for the pulmonary-hypertension component. The primary endpoint is change in six-minute walk distance, a clinically understandable functional measure with direct relevance to symptoms and daily activity.

What to watch in August: placebo-adjusted change in six-minute walk distance, responder analyses, consistency across prespecified subgroups, safety, discontinuations, secondary endpoints and the degree to which the ESC presentation expands beyond the initial topline release.

Merlintrader view: $TENX is one of the strongest overlooked catalysts in the current window. It combines a true Phase 3 value inflection, a defined August readout and enough liquidity to avoid making an immediate financing the only post-data narrative.

The central setup: EyePoint now expects the Phase 3 wet-AMD program to begin reporting in August 2026 with LUGANO, while the identical LUCIA study is now guided for the fourth quarter of 2026. Together, the two trials enrolled more than 900 patients and evaluate DURAVYU, a sustained-delivery vorolanib intravitreal insert, against on-label aflibercept. On July 30, EyePoint also reported early completion of enrollment in the separate Phase 3 COMO and CAPRI diabetic-macular-edema trials, reinforcing the company’s execution record without changing the immediate wet-AMD binary.

The primary objective is non-inferiority in best-corrected visual acuity at weeks 52 and 56. The strategic attraction is not simply maintaining vision: DURAVYU is designed for redosing every six months, so the commercial thesis also depends on sharply reducing the injection burden that limits real-world anti-VEGF care.

The details that matter: the exact non-inferiority result, mean change in vision, percentage of supplement-free eyes, reduction in injection burden, anatomical control, ocular adverse events and consistency between LUGANO and LUCIA. A positive first study followed by confirmation in the second would be much stronger than a single isolated win.

Merlintrader view: $EYPT remains a high-quality pivotal story, but it moves from No. 3 to No. 5 because the second wet-AMD readout is no longer expected to follow immediately: LUCIA is now guided to Q4, outside this page’s September 30 active ranking window. LUGANO in August remains a major standalone clinical test.

The immediate setup: SELLAS is waiting for the event that unlocks the final analysis of REGAL, the pivotal Phase 3 trial evaluating galinpepimut-S, or GPS, as maintenance therapy for patients with acute myeloid leukemia who achieved a second complete remission. The company reported that 78 of the 80 prespecified events had occurred as of May 11, 2026 and said it would announce when the 80th event is reached. No later official company disclosure reviewed for this update confirms that the trigger has occurred.

This makes the timing unusually close but inherently unpredictable. REGAL is driven by overall-survival events rather than a fixed calendar date. The next press release could therefore arrive at any time, but readers must distinguish between two separate milestones: the announcement that the 80th event has occurred and the later release of topline results after database lock, blinded data-review procedures, statistical analysis and unblinding.

What to watch when the trigger arrives: the exact wording of the 80th-event announcement, the expected interval to database lock and topline data, confirmation that the company remains blinded until the planned analysis, and any change to the statistical-analysis process. When topline results are released, the central items will be overall survival, hazard ratio, confidence interval, p-value, censoring, safety and the regulatory path proposed by management.

Merlintrader view: $SLS is one of the closest and most event-sensitive catalysts in the ranking. The setup deserves inclusion because the final trigger can occur without warning, but the waiting-time narrative must not be presented as efficacy evidence. The real binary event is the eventual REGAL topline survival result.

Capricor’s risk profile deteriorated again on July 29, when the FDA Advisory Committee voted 3 Yes and 9 No on whether the available evidence provides substantial evidence of deramiocel effectiveness. The August 22 PDUFA remains formally active, but the company is no longer facing only a hostile staff review. It must now overcome both the review team’s conclusion that efficacy has not been established and a clear negative recommendation from independent advisers. This is an extreme-risk regulatory special situation with a severely impaired approval path, not a balanced pre-PDUFA binary.

HOPE-3 randomized 106 patients and completed its double-blind period in June 2025. Capricor’s sponsor briefing reports a 4.55-percentage-point benefit on PUL 2.0 percent change (p=0.029) and an 11.65-point difference in ranked LVEF change (p=0.041), and argues that the statistical-analysis-plan revisions were finalized before database lock and formal unblinding. FDA staff reached a sharply different conclusion. Under the analysis plan the agency regards as prespecified, the PUL 2.0 treatment difference was 0.66 points (p=0.24) and the LVEF difference was −0.041 percentage points (p=0.97). FDA therefore said HOPE-3 did not meet the primary PUL 2.0 endpoint or the key LVEF endpoint and treated the later positive analyses as post hoc and exploratory because endpoint definitions, statistical models and missing-data methods were changed after the randomized period had ended.

Merlintrader view: $CAPR remains in the ranking only because the August 22 decision is exceptionally close and capable of producing another major repricing. The 3–9 vote sharply worsened the probability-adjusted setup and makes a negative regulatory outcome the central risk. The recommendation is nonbinding and three members voted Yes, so approval cannot be described as impossible; nevertheless, the path is now severely impaired. Its No. 7 placement reflects event immediacy and magnitude, while the negative committee vote prevents it from ranking above the more balanced or newly improved setups.

Telix’s September 11 catalyst concerns Pixclara, a PET imaging agent intended to help evaluate recurrent or progressive glioma and distinguish active disease from treatment-related changes. The FDA accepted the NDA and granted a review path supported by Orphan Drug and Fast Track designations.

The medical need is clear: post-treatment brain imaging can be difficult to interpret, and clinicians may struggle to separate true tumor progression from pseudoprogression or radiation-related changes. A more informative imaging tool could improve treatment decisions, patient selection and clinical-trial assessment.

What matters after approval: final label breadth, reimbursement, U.S. launch timing, production capacity, distribution reliability and evidence that Pixclara changes clinical decision-making. Radiopharmaceutical products require more operational infrastructure than conventional tablets, and execution remains critical even after regulatory success.

Merlintrader view: $TLX is included because it offers a cleaner corporate-risk profile than most catalyst trades. The likely percentage reaction may be smaller, but the event sits inside a durable radiopharma growth platform rather than a single-asset survival story.

The August 7 change: NRx has now disclosed what happened after the July 29 GDUFA goal date for its KETAFREE preservative-free ketamine ANDA. In a Form 8-K filed August 7, the company said FDA’s first-round review found no major deficiencies related to the drug components. FDA did request a labeling update reflecting a change made by the manufacturer of the reference-listed drug, and it identified one remaining Major Deficiency concerning the twist-off cap / luer-lock vial system.

The distinction matters. According to the 8-K, the issue is classified as major because it affects the container closure, not because FDA identified a new clinical, efficacy, safety, drug-substance or drug-product problem. NRx says the same vial is already used in three approved ANDA products, with 11.9 million doses shipped over the prior 12 months without complaints, returns or recalls, and that its own ANDA included functional testing of 3,500 vials from seven manufacturing batches with no observed defects.

What matters next: confirmation that the manufacturer certifications have been submitted in the requested form, FDA acceptance of those certifications, any indication of the renewed review timeline, final ANDA approval, commercial-launch timing, available inventory and the August 10 management call. The key analytical mistake would be to describe KETAFREE as approved already: the path is materially more de-risked, but one formally major packaging deficiency remains open.

Merlintrader view: $NRXP now deserves a place in the Top Ten because the August 7 disclosure transformed a vague post-GDUFA delay into a much more defined regulatory-repair setup. It enters at No. 9 rather than higher because FDA has not provided a new action date and the company’s capital structure remains materially less resilient than the higher-ranked names. The near-term rerating potential is real, but so are timing and financing risks.

Silence Therapeutics enters the ranking because the company has narrowed the SANRECO Phase 2 topline window to August 2026. The study evaluates divesiran, a wholly owned siRNA targeting TMPRSS6, in patients with polycythemia vera who remain dependent on therapeutic phlebotomy despite standard care. The trial is randomized, double-blind and placebo-controlled, making it a more informative test than the encouraging but small open-label Phase 1 experience.

The biological thesis is direct: silencing TMPRSS6 should increase hepcidin, restrict iron availability to the bone marrow and reduce excessive red-blood-cell production. The practical objective is to keep hematocrit below 45% while reducing or eliminating repeated phlebotomies. That creates a clinically understandable endpoint and a potentially differentiated approach in a chronic myeloproliferative disease.

The data details that matter: the proportion of responders in each dosing arm versus placebo, the number and timing of phlebotomies, hematocrit control, durability through the assessment window, symptom scores, iron parameters, injection-site reactions, serious adverse events and treatment discontinuations. The twelve-week regimen would be especially important if it delivers efficacy close to the six-week schedule.

Merlintrader view: $SLN is the best replacement for the final slot because it offers a genuine near-term clinical readout rather than an already completed regulatory event. It ranks tenth because SANRECO is still a relatively small Phase 2 study, but a clean placebo-controlled result could materially reprice the wholly owned divesiran program.